CA2390295A1 - A method for chemoprevention of prostate cancer - Google Patents
A method for chemoprevention of prostate cancer Download PDFInfo
- Publication number
- CA2390295A1 CA2390295A1 CA002390295A CA2390295A CA2390295A1 CA 2390295 A1 CA2390295 A1 CA 2390295A1 CA 002390295 A CA002390295 A CA 002390295A CA 2390295 A CA2390295 A CA 2390295A CA 2390295 A1 CA2390295 A1 CA 2390295A1
- Authority
- CA
- Canada
- Prior art keywords
- prostate cancer
- chemoprevention
- chemopreventive agent
- prevents
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 4
- 230000002113 chemopreventative effect Effects 0.000 title abstract 2
- 229940124443 chemopreventive agent Drugs 0.000 abstract 2
- 239000012627 chemopreventive agent Substances 0.000 abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibits prostate carcinogenesis; and treats prostate cancer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43620899A | 1999-11-08 | 1999-11-08 | |
US09/436,208 | 1999-11-08 | ||
US09/531,472 US6413533B1 (en) | 1998-05-07 | 2000-03-20 | Method for chemoprevention of prostate cancer |
US09/531,472 | 2000-03-20 | ||
PCT/US2000/030658 WO2001034117A1 (en) | 1999-11-08 | 2000-11-08 | A method for chemoprevention of prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2390295A1 true CA2390295A1 (en) | 2001-05-17 |
CA2390295C CA2390295C (en) | 2009-09-29 |
Family
ID=27030854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002390295A Expired - Fee Related CA2390295C (en) | 1999-11-08 | 2000-11-08 | A method for chemoprevention of prostate cancer |
Country Status (20)
Country | Link |
---|---|
US (1) | US6413533B1 (en) |
EP (1) | EP1229903A4 (en) |
JP (1) | JP2003513903A (en) |
KR (2) | KR100793721B1 (en) |
CN (1) | CN1331463C (en) |
AU (1) | AU782444B2 (en) |
BG (1) | BG65794B1 (en) |
CA (1) | CA2390295C (en) |
CZ (1) | CZ20021763A3 (en) |
HK (1) | HK1057000A1 (en) |
HR (1) | HRP20020422A2 (en) |
HU (1) | HUP0203304A3 (en) |
IL (1) | IL149545A0 (en) |
IS (1) | IS6375A (en) |
MX (1) | MXPA02004676A (en) |
NO (1) | NO20022221L (en) |
PL (1) | PL354726A1 (en) |
SK (1) | SK8162002A3 (en) |
WO (1) | WO2001034117A1 (en) |
YU (1) | YU43002A (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
US7737185B2 (en) | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
ATE394099T1 (en) | 2001-11-29 | 2008-05-15 | Gtx Inc | PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY ANDROGEN DEFICIENCY |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
KR20030061474A (en) * | 2002-01-14 | 2003-07-22 | 한미약품 주식회사 | Improved process for the preparation of a cis-racemate compound used as an intermediate in preparing a sertraline |
FI114917B (en) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
US7467119B2 (en) * | 2003-07-21 | 2008-12-16 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
US7483554B2 (en) * | 2003-11-17 | 2009-01-27 | Aureon Laboratories, Inc. | Pathological tissue mapping |
US7461048B2 (en) * | 2003-07-21 | 2008-12-02 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
US7070816B2 (en) * | 2003-12-05 | 2006-07-04 | New Chapter, Inc. | Methods for treating prostatic intraepithelial neoplasia with herbal compositions |
WO2005086068A2 (en) * | 2004-02-27 | 2005-09-15 | Aureon Laboratories, Inc. | Methods and systems for predicting occurrence of an event |
US20080242726A1 (en) * | 2004-07-14 | 2008-10-02 | Podolski Joseph S | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol |
KR20070114187A (en) | 2005-03-22 | 2007-11-29 | 레프로스 쎄라피우틱스 아이엔씨. | Dosing regimes for trans-clomiphene |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
MX2008014825A (en) * | 2006-05-22 | 2008-12-01 | Hormos Medical Ltd | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis. |
WO2009040824A2 (en) * | 2007-09-24 | 2009-04-02 | Ganga Raju Gokaraju | Anti-adipogenic compositions containing piper betel and dolichos bifloras |
EA022760B1 (en) | 2007-10-16 | 2016-02-29 | Репрос Терапьютикс Инк. | Use of trans-clomiphene for prevention or treatment of type 2 diabetes in men |
CN103221052A (en) | 2010-09-16 | 2013-07-24 | 施摩达生物技术有限公司 | Fulvestrant compositions and methods of use |
UA113291C2 (en) | 2011-08-04 | 2017-01-10 | TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS | |
EP2914294A1 (en) | 2012-11-02 | 2015-09-09 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
US4474813A (en) | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
FI77839C (en) | 1982-05-27 | 1989-05-10 | Farmos Oy | FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EFFECTIVE TRIPHENYLALKAN- OCH ALKENDERIVAT. |
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US5595985A (en) | 1989-03-10 | 1997-01-21 | Endorecherche Inc. | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
US4990538A (en) | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
JP3566741B2 (en) * | 1992-10-27 | 2004-09-15 | 日本化薬株式会社 | Autoimmune disease drug |
ATE198271T1 (en) * | 1992-12-01 | 2001-01-15 | Biotie Therapies Oy | SYNDECAN STIMULATION OF CELLULAR DIFFERENTIATION |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
ES2167373T3 (en) | 1993-08-09 | 2002-05-16 | Edward Baral | A METHOD FOR SENSITIZATION OF CANCER CELLS WITH REGARD TO THE LISIS MEDIATED BY MURDER CELLS. |
US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
BR9500758A (en) * | 1994-03-02 | 1995-10-24 | Lilly Co Eli | Pharmaceutical formulations for oral administration |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5441986A (en) * | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
US5635197A (en) | 1995-03-21 | 1997-06-03 | Eli Lilly And Company | Treatment and prevention of prostatic cancer metastasis |
US5629007A (en) | 1995-03-21 | 1997-05-13 | Eli Lilly And Company | Method of preventing prostatic cancer development |
DE19526146A1 (en) * | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylenes, processes for their preparation, pharmaceutical preparations containing these triphenylethylenes and their use for the preparation of medicaments |
US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
US5883118A (en) * | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
US5726202A (en) * | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
US5859045A (en) * | 1996-05-08 | 1999-01-12 | Novo Nordisk A/S Novo Alle | Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate |
ES2151277T3 (en) * | 1996-05-22 | 2000-12-16 | Protarga Inc | COMPOSITIONS INCLUDING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE. |
ZA982819B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
ZA984650B (en) | 1997-06-19 | 1998-12-08 | Orion Corp | Intratumoral administration of triphenylethylenes for the treatment of cancer |
EP1019057B1 (en) * | 1997-08-15 | 2008-10-15 | Duke University | A method of preventing or treating estrogen-dependent diseases and disorders |
GB9805868D0 (en) * | 1998-03-20 | 1998-05-13 | Zeneca Ltd | Anti-tumour agents |
NZ527522A (en) * | 1998-05-07 | 2005-04-29 | Univ Tennessee Res Corp | Use of a chemopreventative agent in a method for chemoprevention of prostate cancer |
CA2346333A1 (en) * | 1998-10-06 | 2000-04-13 | Usda-Ars-Ott | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
-
2000
- 2000-03-20 US US09/531,472 patent/US6413533B1/en not_active Expired - Fee Related
- 2000-11-08 EP EP00978418A patent/EP1229903A4/en not_active Withdrawn
- 2000-11-08 YU YU43002A patent/YU43002A/en unknown
- 2000-11-08 IL IL14954500A patent/IL149545A0/en unknown
- 2000-11-08 MX MXPA02004676A patent/MXPA02004676A/en not_active Application Discontinuation
- 2000-11-08 SK SK816-2002A patent/SK8162002A3/en not_active Application Discontinuation
- 2000-11-08 KR KR1020027005967A patent/KR100793721B1/en not_active IP Right Cessation
- 2000-11-08 AU AU15884/01A patent/AU782444B2/en not_active Ceased
- 2000-11-08 CN CNB008182280A patent/CN1331463C/en not_active Expired - Fee Related
- 2000-11-08 HU HU0203304A patent/HUP0203304A3/en unknown
- 2000-11-08 WO PCT/US2000/030658 patent/WO2001034117A1/en active Search and Examination
- 2000-11-08 PL PL00354726A patent/PL354726A1/en unknown
- 2000-11-08 CA CA002390295A patent/CA2390295C/en not_active Expired - Fee Related
- 2000-11-08 CZ CZ20021763A patent/CZ20021763A3/en unknown
- 2000-11-08 JP JP2001536117A patent/JP2003513903A/en active Pending
- 2000-11-08 KR KR1020067024871A patent/KR20060130788A/en not_active Application Discontinuation
-
2002
- 2002-05-08 NO NO20022221A patent/NO20022221L/en not_active Application Discontinuation
- 2002-05-08 IS IS6375A patent/IS6375A/en unknown
- 2002-05-15 HR HR20020422A patent/HRP20020422A2/en not_active Application Discontinuation
- 2002-05-22 BG BG106738A patent/BG65794B1/en unknown
-
2003
- 2003-11-28 HK HK03108685A patent/HK1057000A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1057000A1 (en) | 2004-03-12 |
EP1229903A1 (en) | 2002-08-14 |
EP1229903A4 (en) | 2006-06-07 |
KR20060130788A (en) | 2006-12-19 |
YU43002A (en) | 2005-09-19 |
PL354726A1 (en) | 2004-02-09 |
WO2001034117A9 (en) | 2002-05-10 |
SK8162002A3 (en) | 2003-03-04 |
HUP0203304A3 (en) | 2006-02-28 |
KR100793721B1 (en) | 2008-01-10 |
JP2003513903A (en) | 2003-04-15 |
IS6375A (en) | 2002-05-08 |
AU1588401A (en) | 2001-06-06 |
HUP0203304A2 (en) | 2003-02-28 |
BG106738A (en) | 2003-02-28 |
CA2390295C (en) | 2009-09-29 |
CN1331463C (en) | 2007-08-15 |
AU782444B2 (en) | 2005-07-28 |
CZ20021763A3 (en) | 2003-02-12 |
KR20020070276A (en) | 2002-09-05 |
MXPA02004676A (en) | 2004-09-10 |
US6413533B1 (en) | 2002-07-02 |
NO20022221L (en) | 2002-06-28 |
IL149545A0 (en) | 2002-11-10 |
HRP20020422A2 (en) | 2004-04-30 |
WO2001034117A1 (en) | 2001-05-17 |
NO20022221D0 (en) | 2002-05-08 |
CN1420765A (en) | 2003-05-28 |
BG65794B1 (en) | 2009-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2390295A1 (en) | A method for chemoprevention of prostate cancer | |
WO1999063826A3 (en) | Agents for combating plant pests | |
WO2002080890A3 (en) | A jasmonate pharmaceutical composition for treatment of cancer | |
MXPA04004674A (en) | Cannabinoid receptor ligands. | |
BG106103A (en) | Estrogen receptor-beta-ligands | |
WO2001098236A3 (en) | 7-phenyl-substituted tetracycline compounds | |
MX9702865A (en) | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-idoles as estrogenic agents. | |
HK1036931A1 (en) | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients. | |
HK1031869A1 (en) | 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds. | |
MY137766A (en) | Exemestane as chemopreventing agent | |
WO2000066528A3 (en) | Quinones for treatment of diseases | |
TNSN03060A1 (en) | A combination comprising combretastatin and anticancer agents | |
AU1843397A (en) | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents | |
BG105197A (en) | Polymorph form of a medicament | |
WO2002067886A3 (en) | Skin composition | |
AU2498100A (en) | Use of an amiodarone compound as antifungal agent | |
GB9907571D0 (en) | Compounds | |
MY121523A (en) | Resorcinol derivatives | |
WO2002020000A3 (en) | Combined estrogen blockade of the breast with exemestane and raloxifene | |
WO2001041709A3 (en) | Methods for treating cell death diseases and inflammation | |
AP1413A (en) | Rescorcinol composition. | |
AU2003286210A1 (en) | Smoke composition | |
WO2001047505A3 (en) | Use of azoles for preventing skin cancer | |
WO2002060405A8 (en) | Veterinary dermatologic composition comprising a sphingoid base and/or a sphingoid base derivative | |
CA2322967A1 (en) | Prophylactic, therapeutic agent for osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20121108 |